A5002883261- Multiple Myeloma Research and Treatments
- Lung Cancer Diagnosis and Treatment
- Chemotherapy-induced organ toxicity mitigation
- Histone Deacetylase Inhibitors Research
- Acute Myeloid Leukemia Research
- Lung Cancer Research Studies
- Reproductive Biology and Fertility
- Cancer Immunotherapy and Biomarkers
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Nigella sativa pharmacological applications
Wuhu Fourth People Hospital
2021-2024
Xian Yang Central Hospital
2021
Objective. To explore the safety of anlotinib capsules combined with PD-1 inhibitor (camrelizumab) in third-line treatment advanced non-small-cell lung cancer (NSCLC) and their effect on serum tumor markers. Methods. 88 patients NSCLC treated Oncology Department our hospital from December 2018 to 2019 were selected as research subjects randomly equally split into single group (STG) (CTG). The levels markers after detected both groups, incidence adverse reactions during was recorded. Results....
Over the past few decades, cyclophosphamide (CP) has been extensively used as a broad-spectrum alkylating agent for treatment of various cancers and solid tumors. However, therapeutic actions on CP are not limited to only cancer cells, it simultaneously exerts significant toxicities healthy cells through instigation oxidative stress damages. induced testicular toxicity is associated with impaired spermatogenesis, reduced sperm functionality, reproductive hormone weight. This study was aimed...
To explore the efficacy and safety of bortezomib or thalidomide combined with recombinant human erythropoietin (rhEPO) in treatment multiple myeloma (MM).